TMPRSS2-ERG has long been studied by the prostate cancer field as an oncogenic gene fusion under the control of the androgen-regulated TMPRSS2 promoter expressed in the majority of prostate cancers (Fig. 7). Here, TMPRSS2 is linked to prostate carcinoma.